Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
latanoprost · 2 trials · 3 indications
| Arm | Type | Description |
|---|---|---|
| latanoprost 75 ug | EXPERIMENTAL | - |
| latanoprost 100 ug | EXPERIMENTAL | - |
| latanoprost 125 ug | EXPERIMENTAL | - |
| latanoprost 50 ug | ACTIVE_COMPARATOR | - |
| 1 | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| latanoprost 75 ug | DRUG | Eligible patients were randomized to receive 1 of 4 different doses of latanoprost (50, 75, 100 or 125 ug/mL). Study medication was supplied in clear bottles. Patients were instructed to instill one drop of study medication in one or both eyes (as instructed by their investigator) once daily in the evening between 7 PM and 9 PM during the entire treatment period. The first dose of study medication was instilled in the evening of the baseline visit and the last dose was instilled in the evening before the Week 4 (Day 28) visit. |
| latanoprost 100 ug | DRUG | Eligible patients were randomized to receive 1 of 4 different doses of latanoprost (50, 75, 100 or 125 ug/mL). Study medication was supplied in clear bottles. Patients were instructed to instill one drop of study medication in one or both eyes (as instructed by their investigator) once daily in the evening between 7 PM and 9 PM during the entire treatment period. The first dose of study medication was instilled in the evening of the baseline visit and the last dose was instilled in the evening before the Week 4 (Day 28) visit. |
| latanoprost 125 ug | DRUG | Eligible patients were randomized to receive 1 of 4 different doses of latanoprost (50, 75, 100 or 125 ug/mL). Study medication was supplied in clear bottles. Patients were instructed to instill one drop of study medication in one or both eyes (as instructed by their investigator) once daily in the evening between 7 PM and 9 PM during the entire treatment period. The first dose of study medication was instilled in the evening of the baseline visit and the last dose was instilled in the evening before the Week 4 (Day 28) visit. |
| latanoprost 50 ug | DRUG | Eligible patients were randomized to receive 1 of 4 different doses of latanoprost (50, 75, 100 or 125 ug/mL). Study medication was supplied in clear bottles. Patients were instructed to instill one drop of study medication in one or both eyes (as instructed by their investigator) once daily in the evening between 7 PM and 9 PM during the entire treatment period. The first dose of study medication was instilled in the evening of the baseline visit and the last dose was instilled in the evening before the Week 4 (Day 28) visit. |
| latanoprost | DRUG | latanoprost 0.005% (1.5 ug) will be administered. A single drop of latanoprost 0.005% will be instilled into both eyes by the investigator. |
Inclusion Criteria: * Male or female, 18 years of age or older. * Primary open angle glaucoma (POAG) or ocular hypertension (OHT) requiring unilateral or bilateral administration of intraocular pressure (IOP) lowering treatment, including patients who were naïve to IOP lowering treatment. * IOP bet...
Latanoprost is used for the treatment of primary open angle glaucoma and glaucoma. It is also studied in ocular hypertension. It is an ophthalmic small molecule being developed by Pfizer, Inc. for these conditions.
Latanoprost is being developed by Pfizer, Inc., which trades on the New York Stock Exchange under the ticker PFE. The drug is an ophthalmic small molecule intended for glaucoma and primary open angle glaucoma.
Latanoprost is in Phase 1 clinical development. It has completed one Phase 1 trial and one Phase 2 trial. The drug is investigational and has not been approved by the FDA.
Latanoprost has been studied in two completed clinical trials. NCT00638742 was a Phase 1 open-label study of latanoprost acid plasma concentrations in pediatric and adult glaucoma patients. NCT01379144 was a Phase 2 study comparing latanoprost 75, 100 and 125 ug/ml to Xalatan in primary open-angle glaucoma and ocular hypertension.
Latanoprost is not the same as Xalatan, but Xalatan was used as a comparator in a clinical trial. In NCT01379144, latanoprost at three different concentrations was compared to Xalatan in patients with primary open-angle glaucoma and ocular hypertension.